查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1373202

活生物治疗产品和微生物 CDMO 市场 - 2018-2028 年全球产业规模、份额、趋势、竞争、机会和预测，按应用、按产品、按製剂类型、按营运规模、按地区和竞争细分

Live Biotherapeutics Products & Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, & Forecast, 2018-2028 Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region & Competition
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球活体生物治疗产品 (LBP) 市场在 2024-2028 年预测期内将以高复合年增长率成长。心血管疾病、糖尿病、慢性呼吸道疾病、癌症和慢性肾臟病等某些慢性疾病在各国的盛行率不断上升，预计将在预测期内为全球活体生物治疗产品和微生物CDMO 市场带来利润丰厚的成长。此外，世界各地的人们对身心健康个人化药物的日益偏好预计将在未来几年推动活体生物疗法产品和微生物 CDMO 市场的成长。

市场区隔

全球活生物治疗产品和微生物 CDMO 市场根据应用、产品、製剂类型、营运规模、公司和地区进行细分。从应用来看，活体生物治疗产品和微生物CDMO市场分为艰难梭菌、克隆氏症、IBS、糖尿病等。根据产品，全球活体生物治疗产品和微生物 CDMO 市场分为 API 和 FDF。依製剂类型，市场分为固体製剂、口服液、注射剂等。根据营运规模，全球活体生物治疗产品和微生物 CDMO 市场分为临床前规模营运、临床规模营运和商业规模营运。

市场参与者

Arranta Bio Holdings LLC.、4D Pharma plc.、Cerbios-Pharma SA、Biose Industrie、Assembly Biosciences, Inc.、Wacker Chemie AG、Quay Pharmaceuticals Ltd.、Bacthera AG、LONZA 和Inpac Probiotics 是全球活性生物治疗药物的主要参与者产品和微生物 CDMO 市场。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球活体生物疗法产品和微生物 CDMO 市场还分为以下几类。

活体生物治疗产品与微生物 CDMO 市场（按应用）：

  • 艰难梭菌
  • 克罗恩病
  • 肠躁症
  • 糖尿病
  • 其他的

活体生物治疗产品和微生物 CDMO 市场（副产品）：

  • 蜜蜂
  • FDF

活生物治疗产品和微生物 CDMO 市场（按配方类型）：

  • 固体製剂
  • 口服液
  • 注射剂
  • 其他的

活生物治疗产品和微生物 CDMO 市场，依营运规模划分：

  • 临床前规模运营
  • 临床规模运营
  • 商业规模营运

活生物治疗产品和微生物 CDMO 市场，按地区：

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 亚太
  • 中国
  • 印度
  • 韩国
  • 澳洲
  • 日本
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 南美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
  • 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

竞争格局

  • 公司概况：全球活体生物治疗产品和微生物 CDMO 市场主要公司的详细分析

可用的客製化：

  • 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球活体生物治疗产品与微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用（艰难梭菌、克隆氏症、IBS、糖尿病、其他）
    • 按产品（API、FDF）
    • 依製剂类型（固体製剂、口服液、注射剂、其他）
    • 依营运规模划分（临床前规模营运、临床规模营运、商业规模营运）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图

第 6 章：北美活体生物治疗产品与微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用
    • 按产品分类
    • 依配方类型
    • 按经营规模
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲活体生物治疗产品与微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用
    • 按产品分类
    • 依配方类型
    • 按经营规模
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区活体生物治疗产品与微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用
    • 按产品分类
    • 依配方类型
    • 按经营规模
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲活体生物治疗产品与微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用
    • 按产品分类
    • 依配方类型
    • 按经营规模
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲活体生物治疗产品和微生物 CDMO 市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市占率及预测
    • 按应用
    • 按产品分类
    • 依配方类型
    • 按经营规模
    • 按国家/地区
  • MEA：国家分析
    • 南非活体生物治疗产品与微生物 CDMO
    • 沙乌地阿拉伯活体生物治疗产品和微生物 CDMO
    • 阿联酋活体生物治疗产品与微生物 CDMO

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Arranta Bio Holdings LLC.
    • 4D Pharma plc.
    • Cerbios-Pharma SA
    • Biose Industrie
    • Assembly Biosciences, Inc.
    • Wacker Chemie AG
    • Quay Pharmaceuticals Ltd.
    • Bacthera AG
    • LONZA
    • Inpac Probiotics

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 15742

Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases

Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world. After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.

Rise in Demand for Personalized Medicines

The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Market Segmentation

Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficle, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Report Scope:

In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Live Biotherapeutics Products and Microbe CDMO Market, By Application:

  • C.difficle
  • Crohns disease
  • IBS
  • Diabetes
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product:

  • APIs
  • FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation:

  • Solid Formulations
  • Oral Liquids
  • Injectables
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation:

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
    • 5.2.2. By Product (APIs, FDFs)
    • 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
    • 5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Product Market Map

6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Product
    • 6.2.3. By Type of Formulation
    • 6.2.4. By Scale of Operation
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value & Volume
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Type of Formulation
        • 6.3.1.2.4. By Scale of operation
    • 6.3.2. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value & Volume
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Type of Formulation
        • 6.3.2.2.4. By Scale of Operation
    • 6.3.3. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value & Volume
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Type of Formulation
        • 6.3.3.2.4. By Scale of Operation

7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Product
    • 7.2.3. By Type of Formulation
    • 7.2.4. By Scale of Operation
  • 7.3 Europe: Country Analysis
    • 7.3.1. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value & Volume
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Type of Formulation
        • 7.3.1.2.4. By Scale of Operation
    • 7.3.2. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value & Volume
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Type of Formulation
        • 7.3.2.2.4. By Scale of Operation
    • 7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value & Volume
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Type of Formulation
        • 7.3.3.2.4. By Scale of Operation
    • 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value & Volume
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Type of Formulation
        • 7.3.4.2.4. By Scale of Operation
    • 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value & Volume
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Type of Formulation
        • 7.3.5.2.4. By Scale of Operation

8. Asia-Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Product
    • 8.2.3. By Type of Formulation
    • 8.2.4. By Scale of Operation
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value & Volume
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Type of Formulation
        • 8.3.1.2.4. By Scale of Operation
    • 8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value & Volume
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Type of Formulation
        • 8.3.2.2.4. By Scale of Operation
    • 8.3.3. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value & Volume
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Type of Formulation
        • 8.3.3.2.4. By Scale of Operation
    • 8.3.4. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value & Volume
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Type of Formulation
        • 8.3.4.2.4. By Scale of Operation
    • 8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value & Volume
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Type of Formulation
        • 8.3.5.2.4. By Scale of Operation

9. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Product
    • 9.2.3. By Type of Formulation
    • 9.2.4. By Scale of Operation
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value & Volume
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Type of Formulation
        • 9.3.1.2.4. BY Scale of Operation
    • 9.3.2. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value & Volume
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Type of Formulation
        • 9.3.2.2.4. By Scale of Operation
    • 9.3.3. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value & Volume
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Type of Formulation
        • 9.3.3.2.4. By Scale of Operation

10. Middle East and Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Product
    • 10.2.3. By Type of Formulation
    • 10.2.4. By Scale of Operation
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value & Volume
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Type of Formulation
        • 10.3.1.2.4. By Scale of Operation
    • 10.3.2. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value & Volume
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Type of Formulation
        • 10.3.2.2.4. By Scale of Operation
    • 10.3.3. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value & Volume
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Type of Formulation
        • 10.3.3.2.4. By Scale of Operation

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Arranta Bio Holdings LLC.
    • 15.6.2. 4D Pharma plc.
    • 15.6.3. Cerbios-Pharma S.A.
    • 15.6.4. Biose Industrie
    • 15.6.5. Assembly Biosciences, Inc.
    • 15.6.6. Wacker Chemie AG
    • 15.6.7. Quay Pharmaceuticals Ltd.
    • 15.6.8. Bacthera AG
    • 15.6.9. LONZA
    • 15.6.10. Inpac Probiotics

16. Strategic Recommendations

17. About Us & Disclaimer